Clinical Trial: Phase I/II Clinical Trial f CD40L-augmented TIL for Patients With Advanced Melanoma

U.S., May 8 -- ClinicalTrials.gov registry received information related to the study (NCT06961357) titled 'Phase I/II Clinical Trial f CD40L-augmented TIL for Patients With Advanced Melanoma' on April 29.

Brief Summary: This is a phase I/II clinical trial of a single dose of CD40L-augmented TIL administered in patients with advanced melanoma (Cohort 1: Cutaneous acral melanoma, cutaneous non-acral melanoma, (n=26); Cohort 2: Mucosal melanoma, uveal melanoma, (n=10)). Patients will undergo an excision of a readily accessible tumor for preparation of TIL. Eligible patients with progressive disease after standard of care therapy will undergo lymphodepletion with cyclophosphamide and fludarabine followed by CD40L-augmented TIL and standard of ...